2. Academic Validation
  3. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

  • J Med Chem. 2023 Dec 14;66(23):15629-15647. doi: 10.1021/acs.jmedchem.3c01233.
David B Freeman 1 2,  Tamara D Hopkins 1 2,  Peter J Mikochik 1 2,  Joseph P Vacca 1 2,  Hua Gao 1 2,  Adel Naylor-Olsen 3,  Sonali Rudra 4,  Huixu Li 5,  Marius S Pop 1 2,  Rosa A Villagomez 1 2,  Christina Lee 1 2,  Heng Li 1 2,  Minyun Zhou 1 2,  Douglas C Saffran 1 2,  Nathalie Rioux 6,  Tressa R Hood 1 2,  Melinda A L Day 1 2,  Michael R McKeown 1 2,  Charles Y Lin 1 2,  Norbert Bischofberger 1 2,  B Wesley Trotter 1 2
Affiliations

Affiliations

  • 1 Kronos Bio, Inc., 301 Binney Street, 2nd Floor East, Cambridge, Massachusetts 02142, United States.
  • 2 Kronos Bio, Inc., 1300 So. El Camino Real Suite 400, San Mateo, California 94402, United States.
  • 3 Naylor Olsen Consulting, LLC, 3369 Saddle Wood Court, Lansdale, Pennsylvania 19446, United States.
  • 4 TCG Lifesciences Private Limited, Block BN, Plot 7, Salt-lake Electronics Complex, Sector V, Kolkata 700091, West Bengal, India.
  • 5 WuXi AppTec (Tianjin) Co., Ltd., 168 NanHai Road, 10th Avenue, TEDA, Tianjin 300457, P. R. China.
  • 6 Certara Strategic Consulting, 100 Overlook Center, Suite 101, Princeton, New Jersey 08540, United States.
PMID: 37967851 DOI: 10.1021/acs.jmedchem.3c01233
Abstract

Transcriptional deregulation is a hallmark of many cancers and is exemplified by genomic amplifications of the MYC family of oncogenes, which occur in at least 20% of all solid tumors in adults. Targeting of transcriptional cofactors and the transcriptional cyclin-dependent kinase (CDK9) has emerged as a therapeutic strategy to interdict deregulated transcriptional activity including oncogenic MYC. Here, we report the structural optimization of a small molecule microarray hit, prioritizing maintenance of CDK9 selectivity while improving on-target potency and overall physicochemical and pharmacokinetic (PK) properties. This led to the discovery of the potent, selective, orally bioavailable CDK9 Inhibitor 28 (KB-0742). Compound 28 exhibits in vivo antitumor activity in mouse xenograft models and a projected human PK profile anticipated to enable efficacious oral dosing. Notably, 28 is currently being investigated in a phase 1/2 dose escalation and expansion clinical trial in patients with relapsed or refractory solid tumors.

Figures
Products